Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

University of Guelph

Epm (ip), Inc.

Joseph Tam

Raphael Mechoulam

Reem Smoum

Simon Benita

Taher Nassar

Linda Parker

Aron Weller

Saja Baraghithy

Christeen Haj

Shira Hirsh

Dror Robinson

Dan Peer

Roger Pertwee

The invention generally concerns a novel class of CB 1 receptor binding molecules and uses thereof.

CB1R receptor blockers with acyclic backbones

The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a cannabidiolic acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.

Cannabinoid acid ester compositions and uses thereof

Cannabidiolic acid esters, compositions comprising them and uses thereof in the treatment of various diseases, conditions and symptoms.

Cannabidiolic acid esters compositions and uses thereof

The present disclosure provides pharmaceutical compositions comprising a fatty acid amide of an amino acid as defined herein, such as oleoyl-&#x3b1;-methyl-serine, or a stereoisomer or salt thereof, for improving, as in increasing or preventing loss of, bone mineral density and/or treating osteoporosis in patients suffering from Prader-Willi syndrome; and their methods of use.

Methods for treatment of Prader-Willi syndrome

Growing community of inventors

Jerusalem, Israel

Joseph Tam